| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Other non-operating income (expense), net | -612 | -424 | -340 | -226 |
| Net loss | -16,288 | -17,398 | -15,922 | -15,360 |
| Unrealized gain (loss) on marketable securities | 33 | -7 | -40 | 217 |
| Comprehensive loss | -16,255 | -17,405 | -15,962 | -15,143 |
| Net loss per share attributable to common stockholders, basic | -0.26 | -0.28 | -0.25 | -0.25 |
| Net loss per share attributable to common stockholders, diluted | -0.26 | -0.28 | -0.25 | -0.25 |
| Weighted-average common stock outstanding, basic | 63,515,372 | 63,006,891 | 62,661,447 | 62,229,463 |
| Weighted-average common stock outstanding, diluted | 63,515,372 | 63,006,891 | 62,661,447 | 62,229,463 |
TREACE MEDICAL CONCEPTS, INC. (TMCI)
TREACE MEDICAL CONCEPTS, INC. (TMCI)